Novo Nordisk’s 42% Rout Hides a Record Pill Launch and a Medicare Windfall

Despite a 42% drop from peak, oral Wegovy's rapid uptake, Medicare coverage, and CagriSema's FDA submission signal a potential turnaround for Novo Nordisk.

The Danish pharmaceutical giant has shed more than two-fifths of its value since peaking at €65.20 a year ago, touching as low as €30.25 and recently changing hands near €37.65. Yet beneath the surface of a stock that has lost 15.6% since January alone, a trio of catalysts is quietly gathering force. Analysts are beginning to argue that the market’s pessimism has overshot, even as the company itself warns of a sharp revenue contraction in 2026.

The most immediate cause of investor gloom was the February data readout for CagriSema, Novo Nordisk’s next-generation obesity candidate. The treatment delivered a 23% weight loss over 84 weeks, falling short of Eli Lilly’s Zepbound at 25.5%. The market had expected at least parity, and the shares plunged 16% on the day. Yet the product has already been submitted to the FDA — in December 2025 — and a decision is expected by the end of 2026. Notably, nearly 51% of patients in the trial achieved a body mass index below 30, a threshold that indicates the drug can still play a major role in the obesity market. The results were presented at a medical congress in New Orleans, and the company continues to highlight the strength of its early-stage pipeline, including a haemophilia drug, NovoEight, whose real-world use was documented in a recent Iraqi study. That rare-disease unit notched 5% revenue growth in the last full year, offering a steady counterweight to the volatility in the obesity franchise.

What has truly shifted the landscape, however, is the launch of the oral version of Wegovy. Approved by the FDA in December 2025, it is the first oral GLP?1 therapy cleared for weight loss, and prescription volumes have been stunning. By April 2026, weekly scripts were exceeding 200,000, and more than one million Americans had started the pill in its first four months. That blistering uptake helped the company report first?quarter revenue of 70.1 billion Danish kroner — down only 4% year on year when many had feared a steeper drop — and the stock gained 3% on the day of the release. European regulators have already recommended approval, and an international rollout is slated for the second half of 2026, starting with the United Arab Emirates.

An even bigger structural shift arrives in July 2026. The Medicare Bridge program will for the first time give eligible U.S. seniors access to Wegovy, with a copay of just $50 a month. Roughly 3.4 million beneficiaries are expected to qualify in the first six months. Because Wegovy holds the broadest label among anti?obesity drugs — including cardiovascular risk reduction — Novo Nordisk is uniquely positioned to capture this new wave of demand. Until now, Medicare did not cover standalone weight?loss medications, making the bridge program a potential game?changer for the company’s U.S. trajectory.

Still, the near?term headwinds are severe. Management has guided for a currency?adjusted revenue decline of 5% to 13% in 2026, with operating profit expected to fall in a similar band. Some published estimates put the contraction at between 4% and 12%, reflecting the same pressures: falling list prices in the United States, cuts to Medicaid coverage for obesity treatments, and the growing competitive force of Eli Lilly. The stock now trades 8.6% below its 200?day moving average of €41.23, and the 14?day relative strength index sits at a neutral 51.2, indicating that neither panic nor euphoria is driving the tape.

What the bears may be missing is the sheer scale of the untapped opportunities. The oral Wegovy launch is rewriting prescription records; Medicare is about to open a multi?billion?dollar senior market; a European approval for the pill is imminent; and the CagriSema decision looms at year?end. The company’s rare?disease unit provides a consistently growing earnings floor. The worst?case scenario appears baked into the current share price, while the upside catalysts remain largely ignored. For patient investors, the risk?reward balance may be tilting back in Novo Nordisk’s favour.